Features of Isotypic Structure of Virus-Specific Systemic Humoral Immune Response in Adult Volunteers Immunized with Inactivated Monovalent Subunit Vaccines against Pandemic Influenza A(H1N1)pdm09
https://doi.org/10.31631/2073-3046-2016-15-2-77-84
Abstract
Keywords
About the Authors
A. A. VasilevaRussian Federation
V. Z. Krivitskaya
Russian Federation
E. M. Vojcekhovskaya
Russian Federation
V. S. Vakin
Russian Federation
E. V. Kuznecova
Russian Federation
E. R. Petrova
Russian Federation
A. A. Go
Russian Federation
N. I. Lvov
Russian Federation
A. A. Sominina
Russian Federation
References
1. Chiu C., Ellebedy A.H., Wrammert J., Ahmed R. B cell responses to influenza infection and vaccination. Curr. Top. Microbiol. Immunol. 2015; 386: 381–398.
2. Gomez Lorenzo M.M., Fenton M.J. Immunobiology of influenza vaccines. Chest. 2013; 143 (2): 502 – 510.
3. Chung E.H. Vaccine allergies. Clin. Exp. Vaccine. Res. 2014; 3 (1): 50 – 57.
4. Lv J., Wang D., Hua Y.H., Pei S.J., Wang J., Hu W.W. Wang X.L., Jia N., Jiang Q.S. Pulmonary immune responses to 2009 pandemic influenza A (H1N1) virus in mice. BMC Infect Dis. 2014; 14:197.
5. Elshina G.A., Lonskaya N.I., Mefed K.M., Puchkova N.G., Chirun N.V., Gorbunov M.А. et al. Results of clinical research of pandemic monovalent influenza vaccine. Вiopreparaty. 2010; 4 (40): 31 – 36 (in Russian).
6. Elshina G.A., Harith S.M., Romanenko V.V., Komleva S.V., Puchkova N.G., Chyrun N.V. et al. The results of the study of the safety and immunogenicity of adjuvanted subunit of domestic pandemic monovalent group Grippol® in children from 6 months to 17 years. Еpidemiology & Vacinal Prevention. 2011; 2 (57): 41 – 46 (in Russian).
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal. Biochem. 1976; 1 (72): 248 – 254.
8. Sominina A.A., Krivitskaya V.Z., Voytsekhovskaya E.M., Medvedeva N.A., Lipina N.V., Potapenko L.B. Practical Guidelines for the diagnosis of viral infections. St. Petersburg: 2005; 21 (in Russian).
9. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 1995; 69 (4): 2075 – 2081.
10. Pedersen G.K., Höschler K., Øie Solbak S.M., Bredholt G., Pathirana R.D., Afsar A. et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine. 2014; 32 (35): 4550 – 4557.
11. El-Madhun A.S., Cox R.J., Haaheim L.R. The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination. J Infect Dis. 1999; 180 (4): 1356 – 1360.
12. Frasca D., Diaz A., Romero M., Mendez N., Landin A.M., Blomberg B. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011 – 2012 influenza vaccine season. Immunity and Ageing. 2013; 10:14.
13. Arankalle V.A., Lole K.S., Arya R.P., Tripathy A.S., Ramdasi A.Y., Chadha M.S. et al. Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One. 2010; 5(10): e13099.
14. Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for influenza vaccines. London; 2001, CPMP/EWP/1045/01.
15. Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014; 5: 520.
16. Reichert T., Chowell G., Nishiura H., Christensen R.A., McCullers J.A. Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BioMed. Central. Infect. Dis. 2010; 10: 5 – 9.
17. Gordon C.L., Johnson P.D., Permezel M., Holmes N.E., Gutteridge G., McDonald C.F. et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin. Infect. Dis. 2010; 50 (5): 672 – 678.
18. Yamamoto T., Mizoguchi Y., Kaneno H., Yamamoto K., Inoue Y., Kawashima H. et al. Serum immunoglobulin G subclass levels and estimated clinical severity caused by possible influenza A(H1N1)pdm2009 infection. J. Infect. Chemother. 2013; 19: 833 – 842.
19. Burton O.T., Oettgen H.C. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol. Rev. 2011; 242(1): 128 – 143.
20. Hofmaier S., Comberiati P., Matricardi P.M. Immunoglobulin G in IgE-mediated allergy and allergen-specific immunotherapy. Eur. Ann. Allergy. Clin. Immunol. 2014; 46 (1): 6 – 11.
21. Chung E.H. Vaccine allergies. Clin. Exp. Vaccine. Res. 2014; 3(1): 50-57.
22. Smith-Norowitz T.A., Kusonruksa M., Wong D., Norowitz M.M., Joks R., Durkin H.G. et al. Long-term persistence of IgE anti-influenza A HIN1 virus antibodies in serum of children and adults following influenza A vaccination with subsequent H1N1 infection: a case study. J. Inflamm Res. 2012; 5: 111 – 116.
23. Julkunen I., Hovi T., Seppälä I., Mäkelä O. Immunoglobulin G subclass antibody responses in influenza A and parainfluenza type 1 virus infections. Clin. Exp. Immunol. 1985; 60 (1): 130 – 138.
24. Monteiro R.C. Role of IgA and IgA fc receptors in inflammation. J. Clin. mmunol. 2010; 30 (1): 1 – 9.
25. Li Z.N., Lin S.C., Carney P.J., Li J., Liu F., Lu X. et al. IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States. Clin. Vaccine. Immunol. 2014; 21 (8): 1054 – 1060.
Review
For citations:
Vasileva A.A., Krivitskaya V.Z., Vojcekhovskaya E.M., Vakin V.S., Kuznecova E.V., Petrova E.R., Go A.A., Lvov N.I., Sominina A.A. Features of Isotypic Structure of Virus-Specific Systemic Humoral Immune Response in Adult Volunteers Immunized with Inactivated Monovalent Subunit Vaccines against Pandemic Influenza A(H1N1)pdm09. Epidemiology and Vaccinal Prevention. 2016;15(2):77-84. (In Russ.) https://doi.org/10.31631/2073-3046-2016-15-2-77-84